Application Note

Agilent
Trusted Answers

Ultra-Fast Analysis of Nitrosamines Using SPE-QQQ

Authors

Kevin Truempi and
Kevin McCann
Agilent Technologies, Inc.

Introduction

Several highly sensitive quantitative methods have been developed for the analysis of nitrosamines using mass spectrometry.[1] However, these methods rely on chromatographic separations that take several minutes per sample. Rapid, robust screening and quantitation of impurities is an essential analytical tool for a wide variety of laboratories. High-throughput environments must be able to perform these analyses in a way that ensures productivity, minimizes costs, and eliminates backlog. The use of solid phase extraction triple quadrupole mass spectrometry (SPE-QQQ) allows the ultra-fast analysis of samples without compromising analytical fidelity.

This work explores the simultaneous quantitation of a panel of nitrosamines in less than 15 seconds per injection. An existing U.S. Food and Drug Administration (US FDA) analytical method[2] was reproduced, then additional nitrosamines were added to assess feasibility and ease of expanding the panel.



N-Nitrosoethylmethylamine (NMEA) N-Nitrosopyrrolidine (NPyR) N-Nitrosopiperidine (NPIP)

Figure 1. Three nitrosamines studied as proof-of-concept additions to FDA's RapidFire method for the analysis of nitrosamine impurities.

Experimental

Instrumentation

Instrumentation for the SPE-QQQ analysis consisted of an Agilent RapidFire high-throughput mass spectrometry system coupled to an Agilent Ultivo triple quadrupole LC/MS (Figure 2). Online solid phase extraction (SPE) was performed using a graphitic carbon cartridge to separate target analytes from salts and any other interferences present in the samples.

Chemicals and reagents

Nitrosamine standards, LC/MS grade methanol, and formic acid were purchased from Sigma-Aldrich, St. Louis, MO, USA.

Method

The automated trap, wash, and elute cycle was optimized to achieve an analysis time of less than 15 seconds per injection (Figure 3).

Instrument settings

Parameter	Value	
RapidFire Conditions		
Buffer A	Water + 0.1% formic acid	
Buffer B	Methanol + 0.1% formic acid	
SPE Cartridge	Graphitic Carbon, Type D (G9206A)	
Program	State	Time (ms)
	Aspirate	600
	Load/Wash	2,000
	Elution	7,000
	Re-Equilibrate	2,000
Ultivo Conditions		
Ion Mode	APCI	
Polarity	Positive	
Drying Gas Temperature	300 °C	
Drying Gas Flow	6 L/min	
Nebulizer	55 psi	
APCI Heater	350 °C	
APCI Needle	4 µA	
Capillary Voltage	3,000 V	

Figure 2. Agilent RapidFire 400 high-throughput mass spectrometry system coupled to an Agilent Ultivo triple quadrupole LC/MS.



Figure 3. RapidFire injection cycle.

Results and discussion

Ultra-fast data acquisition

Injections were made at a rate of approximately 12.5 seconds per sample while data were acquired by triple quadrupole mass spectrometry. Figure 4 shows 72 injections acquired in under 15 minutes; several blanks were run between calibration levels to assess carryover.

Reproducible and accurate results

Triplicate injections of each calibrator demonstrated excellent reproducibility. Coefficients of variation range from 4.5 to 9.0% for NPIP (Figure 4) and are representative of all analytes. Excellent linearity is also observed, with R^2 ranging from 0.997 to 0.999 (Figure 5).



Figure 4. Triplicate injections of a six-point calibration curve for NPIP. Six blank injections were made between each calibration level to evaluate carryover.



Figure 5. Calibration from 1 to 100 ng/mL for NDBA and NPIP. Calibration from 5 to 100 ng/mL for NPyR and NMEA.

Conclusion

The US FDA's method for rapid analysis of nitrosamine impurities has been replicated with consistent results. Further proof-of-concept work demonstrates the simplicity of adding additional nitrosamine analytes, without any significant method development.

References

1. FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls. (2019, November 13). FDA. Retrieved April 15, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan
2. Development and validation of a RapidFire-MS/MS method for screening of nitrosamine carcinogen impurities…in ARB drugs. (2019, July 24). FDA. Retrieved April 15, 2020. https://www.fda.gov/media/125477/download
3. Information about Nitrosamine Impurities in Medications. (2020, February 3). FDA. Retrieved April 15, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications

www.agilent.com/chem

DE44376.3473842593

Printed in the USA, July 7, 2021
5994-3752EN

Agilent
Trusted Answers